Twenty @entity1 with @entity739 were initially treated with high-dose @entity2245 (40 to 50 mg/kg/day) and @entity1092 (40 to 50 mg/kg/day). Three became @entity410 free. For the remaining 17 @entity1 , low-dose synthetic ACTH (0.01 mg [0.4 IU]/kg/day) was added to the regimen. One month after the end of ACTH therapy, 13 @entity1 were @entity410 free. Thus 16 @entity1 in total(80%) were free of @entity410 (group A). The treatment was ineffective for the remaining 4 @entity1 (20%; group B). During the following for a mean period of 64 months (range, 48 to 83 months), 9 in group A had a relapse of @entity302 . However, only 4 in this group had @entity302 at the end of the study (5-7 years of age), all of which were partial and infrequent. In group B, two had frequent intractable @entity410 , and one was @entity410 free at the end of the study. One died at the age of 1 year. In group A, 2 @entity1 showed normal or subnormal mental development. Mild, moderate and severe @entity1032 were seen in 3, 4 and 7 @entity1 respectively. In group B, all @entity1 showed severe @entity1032 . In this study, the rate of evolution into intractable @entity302 was low, but long-term mental development was poor. @entity410 control by itself seemed to be insufficient to improve long developmental prognosis of @entity739 .

[ @entity410 and developmental prognosis of @entity739 --combination therapy with high-dose XXXX , valproate and low-dose ACTH].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures', 'Seizure'] @entity1032 :: ('MESH:D008607', 'Disease') :: ['mental retardation'] @entity2245 :: ('MESH:D025101', 'Chemical') :: ['vitamin B6'] @entity1092 :: ('MESH:D014635', 'Chemical') :: ['valproate'] @entity739 :: ('MESH:D013036', 'Disease') :: ['West syndrome'] @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic seizures', 'epilepsy']
@entity2245 :: (MESH:D025101,Chemical) :: ['vitamin B6']
